RIP1 inhibitor - Denali Therapeutics

Drug Profile

RIP1 inhibitor - Denali Therapeutics

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc
  • Class Antidementias; Small molecules
  • Mechanism of Action Receptor-interacting protein serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 25 Aug 2016 Denali Therapeutics acquires Incro Pharmaceuticals
  • 25 Aug 2016 Denali Therapeutics plans a phase-I trial for Neurodegenerative disorders in Europe
  • 25 Aug 2016 Incro Pharmaceuticals in-licenses RIP1 inhibitors from Harvard University before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top